Distinguishing Between Cachexia, Sarcopenia and Protein Energy Wasting in End-Stage Renal Disease Patients on Dialysis


Published in:
Palliative Medicine and Hospice Care

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
©2016 Reid J. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Download date: 16. Oct. 2018
Distinguishing Between Cachexia, Sarcopenia and Protein Energy Wasting in End-Stage Renal Disease Patients on Dialysis

Joanne Reid, PhD 1*; Helen R. Noble, PhD 1; Adrian Slee, PhD 2; Andrew Davenport, MD 3; Ken Farrington, MD 4; Denis Fouque, PhD 5; Kamyar Kalantar-Zadeh, PhD 6; Sam Porter, PhD 7; David Seres, MD 8; Miles D. Witham, PhD 9; Alexander P. Maxwell, PhD 10

1School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK
2Lecturer in Nutrition, London South Bank University, UK
3Consultant Nephrologist, Royal Free Hospital, 103 Borough Rd, London SE1 0AA, UK
4Consultant Nephrologist, East and North Hertfordshire Trust, Coreys Mill Ln, Stevenage SG1 4AB, UK
5Professor of Nephrology, Université de Lyon, 92 Rue Pasteur, 69007 Lyon, France
6Chief, Division of Nephrology and Hypertension, Professor of Medicine, Pediatrics and Public Health, University of California USA, CA, USA
7Professor of Nursing Sociology, Department of Social Sciences and Social Work, Bournemouth University, UK
8Director of Medical Nutrition and Associate Professor of Medicine, Columbia University, New York, USA
9Clinical Reader in Ageing and Health, University of Dundee, Nethergate, Dundee DD1 4HN, UK
10Consultant Nephrologist, Professor of Renal Medicine, Belfast Health and Social Care Trust, UK; School of Medicine, Queen’s University Belfast, UK

Patients with end-stage renal disease (ESRD) receiving dialysis can have altered nutritional status and body composition due to dietary restrictions, level of physical activity, co-morbidities, metabolic alterations and inflammation. As such, weight loss or wasting is common among this population with up to 75% of adults with ESRD undergoing maintenance dialysis displaying some evidence of wasting. There are several forms of loss of lean muscle mass or wasting in ESRD, including ‘protein energy wasting’, ‘cachexia’, and ‘age-related sarcopenia’ and these terms are often used interchangeably alongside ‘malnutrition’ in current care. Limited understanding of the differences between such terms is arguably a barrier to accurate recognition and management of these disorders in patients with ESRD. For instance, a recent European study of over 700 dietetic participants concluded that only 13% of health care professionals who could differentiate between malnutrition, starvation, cachexia and sarcopenia.

3 Such knowledge is pertinent as for example, loss of muscle mass is a key feature in both sarcopenia and cachexia, but most patients with sarcopenia are not cachectic, as muscle wasting occurs with aging.

Research has informed a disease specific definition (and associated diagnostic criteria) for protein energy wasting (PEW) in renal disease, and while cachexia in ESRD is seen as the severe form of PEW, there remains no consensus definition or diagnostic criteria to differentiate between PEW and cachexia. What distinguishes PEW from cachexia is that the latter relates to only severe forms of metabolic depletion. However, PEW can refer to mild reduction of lean muscle mass or depletion of energy stores. Alongside, the lack of disease specific definition or diagnostic criteria for cachexia, there is also no such disease specific criterion for sarcopenia in renal disease. The evidence-based development of these terms is essential to enable health care professionals to clearly identify and differentiate between such conditions. This greater understanding of the difference and interplay between cachexia, PEW and sarcopenia in ESRD.
has the potential to inform the development and testing of targeted novel therapeutic treatments aimed at reducing morbidity and mortality. Significant progress has been made defining cachexia and its associated clinical characteristics in patients with cancer. An agreed definition and classification of cancer cachexia has contributed to enhanced standardization of screening, staging assessment and management. This is a model that could be applied to cachexia in other chronic conditions, such as ESRD.

Reflecting the current evidence base, Table 1 outlines the characteristics of age-related sarcopenia, cachexia in chronic illness, and PEW in renal disease. These characteristics and associated pathologies are reviewed elsewhere in the literature and while the diagnostic criteria share similarities they are not identical. For example, weight loss is part of the definition of both cachexia in chronic illness and PEW in renal disease, but the duration of the weight loss differs (weight loss of 5% over 6 months in cachexia as opposed to 5% over 3 months in PEW). Additionally, the diagnostic criteria for cachexia in chronic illness emphasizes lean mass functionality (decreased muscle strength and fatigue), which is also common in sarcopenia of old age, although the defining characteristics of sarcopenia emphasize the importance of gait speed which cachexia does not. Furthermore, anaemia is considered a feature of cachexia in chronic illness, but not of PEW in renal disease or sarcopenia of old age.

As seen in Table 1, there are both variations and commonalities in the known clinical characteristics of sarcopenia, cachexia and PEW in a renal population. This may be reflective of the poly-symptomatic nature of ESRD. However, it makes the diagnosis of any of the three conditions more complex. Effectively distinguishing between these three conditions in ESRD is important, acknowledging that elements of sarcopenia and PEW may be present in cachexia, as interventional strategies may be very different for each. Work on delineating key clinical characteristics of PEW in renal disease has progressed extensively and cachexia is viewed as a severe form of PEW. However, the diagnostic criteria for cachexia in ESRD, as opposed to PEW, have not been agreed. This is significant as cachexia may involve additional metabolic abnormalities that are potentially amenable to therapeutic intervention.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Sarcopenia of old age</th>
<th>Cachexia in chronic illness</th>
<th>Protein energy wasting in renal disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person must have column iii plus column iv or v.</td>
<td>Oedema-free “unintentional” weight loss of at least 5% in 12 months or less in the presence of underlying illness. In cases where weight loss cannot be documented, a BMI&lt;18.5 kg/m² or a drop from higher BMI to a BMI=20 kg/m² is sufficient.</td>
<td>Unintentional weight loss over time: 5% over 3 months or 10% over 6 months. Oedema-free BMI&lt;23 kg/m² for example, post-dialysis dry weight.</td>
<td>Serum albumin&lt;3.8 g/dL (bromocresol green). Serum prealbumin (transferrin)&lt;30 mg/dL, for maintenance dialysis patients only; levels may vary according to GFR level for patients with CKD stages 2-5). Serum cholesterol&lt;100 mg/dL.</td>
</tr>
<tr>
<td>Gait speed&lt;0.8 metres per second.</td>
<td>Low muscle mass&lt;7.23-7.26 kg/m² for men and&lt;5.5-5.67 kg/m² for women using appendicular lean tissue/height² by DEXA. Low fat-free mass index. Total body fat percentage&lt;10%. Reduced mid-arm muscle circumference area - reduction &gt;10% in relation to 50th percentile of reference population. Muscle wasting: reduced muscle mass 5% over 3 months or 10% over 6 months.</td>
<td>Decreased muscle strength (lowest tertile). Not stated.</td>
<td>Not stated</td>
</tr>
<tr>
<td>Not stated, but weight gain is expected in obese sarcopenia whereas weight loss can occur otherwise.</td>
<td>Increased inflammatory markers CRP (&gt;3.0 mg/L), IL-6&gt;3.0 pg/mL. Anemia (&lt;10 g/dL). Low serum albumin (&lt;3.5 g/dl BGG or &lt;3.2 BCP).</td>
<td>Decreased dietary intake&lt;20 kcal/kg for at least 2 months.</td>
<td>Not stated, but often some decline in appetite and/or protein and energy is observed.</td>
</tr>
<tr>
<td>Not stated, but it is expected that serum creatinine relative to kidney function declines.</td>
<td>Low fat-free mass index. Lean tissue depletion i.e. mid upper arm muscle circumference&lt;10th percentile for age and gender; appendicular skeletal muscle index by DEXA &lt;5.45 kg/m² in females and&lt;7.25 kg/m² in males.</td>
<td>Unintentional low dietary protein intake&lt;0.80 g/kg/day for at least 2 months for dialysis patients or&lt;0.6 g/kg/day for patients with CKD stages 2-5. Unintentional low dietary energy intake&lt;25 Kcal/kg/day for at least 2 months.</td>
<td>Person must have at least three out of the four columns i,ii,iii and vi and at least one test from each of the selected columns.</td>
</tr>
</tbody>
</table>

Table 1: Defining characteristics of sarcopenia of old age, cachexia in chronic illness and protein-energy wasting in renal disease.
What should the next steps be? Adoption of a disease-specific definition of cachexia in ESRD would contribute to standardization of screening, assessment and management strategies that are aimed at improving morbidity and mortality in these patients. Such a definition needs to be derived in such a way to distinguish cachexia from both sarcopenia and PEW, should define a population group with a different prognosis from PEW, and needs to reflect our understanding of the pathophysiology (particularly the role of inflammation) of cachexia in other conditions such as cancer, heart failure and COPD. Such a definition would greatly facilitate screening, diagnosis and development of treatments for this life-limiting complication of end stage renal disease.14,15

REFERENCES


